Marc Carrier, MD

MD, MSc
Ottawa Hospital Research Institute, Ottawa, ON, Canada
Ottawa, Ontario, Canada

Dr. Marc Carrier, M.D., MSc, FRCPC, is Head of the Division of Hematology at The Ottawa Hospital, a Professor in the Faculty of Medicine, Department of Medicine and Senior Scientist in the Clinical Epidemiology Program of The Ottawa Hospital Research Institute. He holds a Tier 1 Research Chair in Venous Thromboembolism and Cancer from the Faculty of Medicine at the University of Ottawa.

Presentation(s):

• OC 01.3 - Systemic and catheter-directed thrombolysis in high and intermediate-high risk pulmonary embolism: a systematic review with meta-analysis

  Saturday, June 24, 2023
  13:30 – 13:45 ET

• OC 05.2 - Impact of heparin on disease state transition in hospitalized, non-critically ill patients with COVID-19; secondary analysis of an international multi-platform RCT

  Saturday, June 24, 2023
  13:15 – 13:30 ET

• OC 29.4 - Impact of symptom duration on clinical outcomes in hospitalized, non-critically ill patients with COVID-19; secondary analysis of an international multi-platform RCT

  Sunday, June 25, 2023
  15:30 – 15:45 ET

• PB0052 - Heparin type & clinical outcomes in hospitalized, non-critically ill patients with COVID-19: secondary analysis of an international multi-platform RCT

  Sunday, June 25, 2023
  18:30 – 19:30 ET

• PB0479 - The ABC-bleeding score for prediction of on-treatment clinically relevant bleeding in patients with unprovoked venous thromboembolism: results from the prospective PLATO-VTE study

  Sunday, June 25, 2023
  18:30 – 19:30 ET

• PB0486 - Effect of Age on Risk for Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis

  Sunday, June 25, 2023
  18:30 – 19:30 ET

• OC 36.2 - Machine-learning based risk prediction of cancer associated thrombosis: internal, external, and pre-clinical validation studies

  Monday, June 26, 2023
  11:00 – 11:15 ET

• OC 40.5 - Risk of All-Cause Mortality following Anticoagulant Cessation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-Analysis

  Monday, June 26, 2023
  15:45 – 16:00 ET

• OC 46.1 - Absolute quantitative proteomics for occult cancer screening in patient with unprovoked venous thromboembolism: results from the prospective PLATO-VTE study

  Monday, June 26, 2023
  14:45 – 15:00 ET

• PB0947 - The Risk of Venous Thromboembolism in Primary Central Nervous System Lymphoma: A Systematic Review

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB0965 - Delphi Survey of Canadian Physicians to Determine Optimal Anticoagulant Treatment Approaches for Patients with Cancer and Splanchnic Venous Thrombosis

  Monday, June 26, 2023
  18:30 – 19:30 ET

• OC 54.1 - Effectiveness and Safety of Rivaroxaban and Low Molecular-Weight Heparin in Cancer-Associated Venous Thromboembolism: A Meta-Analysis of OSCAR Programme Findings

  Tuesday, June 27, 2023
  10:45 – 11:00 ET

• OC 54.4 - Multinational Cohort Analysis of Intracranial Hemorrhage Outcomes in Patients with Brain Tumors Receiving Anticoagulation (ABC Study)

  Tuesday, June 27, 2023
  11:30 – 11:45 ET

• PB1312 - “The doctor says so” – Patient Values and Preferences Regarding Resumption of Oral Anticoagulation After Gastrointestinal Bleeding

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1355 - Long vaccine-induced immune thrombotic thrombocytopenia: a case report

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1487 - Venous Thromboembolism and Major Bleeding Risk in Hospitalized Obese Patients Receiving Thromboprophylaxis with Enoxaparin

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• OC 71.6 - Management of Cancer Associated Thrombosis

  Wednesday, June 28, 2023
  10:15 – 11:30 ET

• OC 71.3 - The prevalence of relevant drug-drug interactions and associated clinical outcomes in patients with cancer-associated thrombosis on concurrent anticoagulation and anticancer therapies

  Wednesday, June 28, 2023
  10:45 – 11:00 ET